Market Context — Why This Technology, Why Now

A significant global trend is the increasing understanding of the gut microbiome's profound impact on human health, driving demand for microbiome-based therapeutics and functional foods. Concurrently, the healthcare industry is shifting towards personalized medicine, where treatments are tailored to individual biological profiles. This technology aligns perfectly with these trends, offering a targeted, biological intervention for IBD and potential applications in preventive health, addressing a market seeking more natural and holistic solutions beyond traditional pharmaceuticals.

Key Competitive Advantages
01

Offers a novel therapeutic mechanism: Paraprevotella bacteria inhibit trypsin activity, fundamentally improving the gut environment and providing a new IBD treatment option.

02

Proven reliability by national research institute: Demonstrated implementation and licensing by RIKEN validate the technology's practicality and safety, reducing adoption risk.

03

Secures long-term market exclusivity until 2044: Patent protection until November 2044 deters competitors and provides a strong foundation for long-term business strategy.

Market Opportunity
Inflammatory Bowel Disease (IBD) Therapeutics
$13.5B globally (AI est.)
The increasing number of IBD patients and limitations of existing therapies drive a strong demand for novel and effective treatments, leading to market expansion.
Global pharmaceutical companies specializing in gastroenterology Biotech firms developing microbiome-based therapies Contract Research Organizations (CROs) for clinical trials
Functional Foods and Supplements Market
$8B in Japan (AI est.)
Growing interest in gut flora and increased demand for probiotic products for health maintenance and disease prevention suggest potential for preventive applications.
Major food and beverage corporations Nutraceutical and supplement manufacturers Health-focused consumer goods companies
Personalized Medicine and Precision Health
$3.5B globally (AI est.)
Advancements in personalized medicine, offering tailored treatments based on individual gut environments, position this technology as a core component for optimal therapy and prevention.
Diagnostic companies developing microbiome analysis tools Healthcare providers focusing on personalized nutrition Digital health platforms integrating gut health data
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent establishes broad and specific protection for compositions containing Paraprevotella bacteria as an active ingredient for inhibiting trypsin activity, with 9 claims. It is a robust right, having been granted after examination against 7 prior art documents, demonstrating its stability and strength against existing technologies. The involvement of a reputable patent firm and RIKEN as the applicant further enhances its value.

Competitive White Space

This patent specifically covers Paraprevotella bacteria for trypsin activity inhibition. White space exists for exploring other microbial strains or combinations for IBD, or investigating additional therapeutic mechanisms of Paraprevotella beyond trypsin modulation for other inflammatory conditions.

Economic Impact
~$65 million/year estimated new market capture (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming approximately 200,000 IBD patients in Japan, with an existing treatment market of ~$1 billion annually (AI est.). If this technology is launched as a new drug, it could reach about 5% of the market (approximately 10,000 patients) who find existing drugs ineffective or have concerns about side effects. Estimating an annual treatment cost of ~$6,500 per patient, this could contribute to capturing a new market segment of ~$65 million annually (AI est.).

Speed to Market
5× faster than in-house development
This technology benefits from existing implementation and licensing track records by RIKEN, ensuring foundational research data is complete. This significantly reduces the 5+ years typically required for in-house R&D. The cultivation and formulation of Paraprevotella bacteria are highly compatible with existing biopharmaceutical manufacturing processes, facilitating a smooth transition to product development and clinical trials. With a proven technological base, product preparation could be accelerated to approximately 1 year.
Competitive Positioning

X: Contribution to Root Cause Treatment
Y: Safety and Long-Term Sustainability

Business Models & Applications
💊 Pharmaceutical Development & Licensing
Develop IBD therapeutics based on this technology and license manufacturing and sales rights to pharmaceutical companies. Expects royalty income and upfront payments.
🍎 Functional Food & Supplement Development
Develop functional foods and supplements with specific Paraprevotella bacteria as active ingredients, supplying them to health food manufacturers.
🤝 Joint Research & Development
Collaborate with existing pharmaceutical or food manufacturers on clinical research and product development using this technology, diversifying risk and accelerating market entry.
Adjacent Application Opportunities
👶 Infant Healthcare
Allergy Prevention & Improvement Supplements for Infants
Infant allergies are closely linked to gut health. Applying this technology to probiotic products could help prevent allergic diseases or alleviate symptoms. It offers high safety and potential for long-term use in a market seeking gentle solutions.
🏋️‍♂️ Sports Nutrition & Health Foods
Gut Health Supplements for Athletes
Intense exercise can cause gut stress and immune suppression, impacting athlete performance. This technology could support athlete conditioning and performance by improving gut environment and suppressing inflammation, addressing a market focused on peak physical health.
🧠 Mental Health
Mental Wellness Support Based on Gut-Brain Axis
The gut-brain axis, linking gut bacteria and brain function, is a growing area of interest. By improving gut health, this technology could contribute to stress reduction and mood stability, offering a novel approach for mental health support products in a rapidly expanding market.
Integration Roadmap — Estimated 28-Month Deployment
Phase 1: Technology Evaluation & Development Planning
Duration: 4 months
Detailed evaluation of existing research data and patent information for this technology. Develop product development direction and clinical trial plans for the adopting company. Initial consideration of target diseases and formulation will also be conducted.
Phase 2: Clinical Trials & Product Development
Duration: 15 months
Initiate non-clinical and human clinical trials (investigational new drug trials) based on the developed plan. Concurrently, optimize the Paraprevotella bacteria cultivation process and develop pharmaceutical formulations as a medicinal composition.
Phase 3: Manufacturing & Market Launch
Duration: 9 months
Based on clinical trial results, establish manufacturing processes and quality control systems. Following regulatory approval, promptly begin product manufacturing and market introduction, executing sales strategies.
Technical Feasibility
This technology is presumed to have established basic cultivation and formulation techniques, given its existing implementation and licensing track records by RIKEN. The patent claims clearly specify Paraprevotella bacteria as the active ingredient, suggesting relatively easy application to existing microbial drug and biopharmaceutical manufacturing facilities. It possesses a technical foundation that allows for early implementation through modification and optimization of existing production lines, without requiring significant new capital investment.
Success Scenario
Implementing this technology could offer a new treatment option for Inflammatory Bowel Disease patients who have not responded to existing therapies. This is expected to improve patient symptoms and significantly enhance their quality of life. In the long term, it could also contribute to reducing healthcare costs associated with IBD and extending healthy lifespans through a preventive approach. By introducing it to the market as a new drug, adopting companies could establish a competitive advantage in the pharmaceutical market and secure new revenue streams.
Patent Record
APPLICATION NO.
特願2023-198897
REGISTRATION NO.
7588436
FILING DATE
2023/11/24
GRANT DATE
2024/11/14
EXPIRATION DATE
2043/11/24
PATENT HOLDER
国立研究開発法人理化学研究所
Examination History
2023年11月29日
出願審査請求書
2023年12月01日
手続補正書（自発・内容）
2024年10月29日
特許査定